Target intelligence / Profile preview

Midbrain dopaminergic neuron (mDA neuron)

Target
mDA neuron
Molecular classification
Neuron, Neurotransmitter-producing cell, Other
01

Overview

Midbrain dopaminergic neurons are a class of neurons primarily located in the substantia nigra and ventral tegmental area of the human midbrain. They synthesize and release dopamine—a central neurotransmitter for voluntary movement and reward-driven behaviors. These neurons form distinct projection pathways: the nigrostriatal pathway (crucial for motor control) and the mesocorticolimbic pathway (involved in reward, motivation, and cognition). Degeneration or dysfunction of these neurons is central to the pathophysiology of Parkinson’s disease, as well as contributing to schizophrenia and addiction. Pharmacological therapies commonly target these neurons directly or modulate their activity through dopamine receptor interaction and metabolic pathways. Their functional diversity, anatomical projection specificity, and importance in health and disease make them critical targets for neuroscientific research and drug development.

Other names
midbrain dopamine neuronmesodiencephalic dopaminergic neuronmdDA neurondopaminergic neuron of the ventral tegmental areadopaminergic neuron of the substantia nigra
02

Mechanism of action

Dopamine replacement (L-DOPA is converted to dopamine within remaining neurons); Dopamine receptor agonism (agonists stimulate dopamine receptors on postsynaptic neurons); Dopamine receptor antagonism (antipsychotics inhibit dopamine receptors); Modulation of dopamine metabolism and reuptake (MAO inhibitors reduce breakdown, promoting dopamine signaling)

03

Biological functions

Voluntary movement controlReward processing and motivationRegulation of emotion and working memoryLearning and attention
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease)Neuropsychiatric disease (schizophrenia, drug addiction)Other (motor and cognitive disorders)
05

Safety considerations

Dyskinesia and motor fluctuations with chronic dopaminergic therapyPsychiatric side effects (hallucinations, impulse control disorders)Drug tolerance and on-off phenomenaNeurotoxicity risk in gene or cell-based therapies
06

Interacting drugs

Levodopa (L-DOPA)

3 more in the full profile.

07

Biomarkers

Dopamine transporter loss (PET imaging)Neuromelanin-sensitive MRI changesDecreased dopamine metabolites in cerebrospinal fluid

Beyond the preview

Go deeper on Midbrain dopaminergic neuron (mDA neuron).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Midbrain dopaminergic neuron (mDA neuron).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call